NSD1 inhibition has been shown to enhance sensitivity to cisplatin and carboplatin in head and neck cancer cell lines [47,48], but the impact of loss-of-function mutations in NSD1 on cetuximab response is unknown. This evidence concerns the gene NSD1 and head and neck cancer.